Literature DB >> 17194174

Increase in nonfatal digestive perforations and haemorrhages following introduction of selective NSAIDs: a public health concern.

Douglas J Watson, Elham Rahme, Nancy C Santanello.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17194174     DOI： 10.2165/00002018-200730010-00009

Source DB:  PubMed          Journal:  Drug Saf        ISSN： 0114-5916            Impact factor:   5.606


× No keyword cloud information.
  10 in total

1.  Increase in nonfatal digestive perforations and haemorrhages following introduction of selective NSAIDs: a public health concern.

Authors:  Louise Barnard; Dominic Lavoie; Nancy Lajeunesse
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

2.  Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.

Authors:  F E Silverstein; G Faich; J L Goldstein; L S Simon; T Pincus; A Whelton; R Makuch; G Eisen; N M Agrawal; W F Stenson; A M Burr; W W Zhao; J D Kent; J B Lefkowith; K M Verburg; G S Geis
Journal:  JAMA       Date:  2000-09-13       Impact factor: 56.272

3.  Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.

Authors:  C Bombardier; L Laine; A Reicin; D Shapiro; R Burgos-Vargas; B Davis; R Day; M B Ferraz; C J Hawkey; M C Hochberg; T K Kvien; T J Schnitzer
Journal:  N Engl J Med       Date:  2000-11-23       Impact factor: 91.245

4.  Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: a randomized, double-blind, placebo-controlled trial. The Rofecoxib Osteoarthritis Endoscopy Multinational Study Group.

Authors:  C Hawkey; L Laine; T Simon; A Beaulieu; J Maldonado-Cocco; E Acevedo; A Shahane; H Quan; J Bolognese; E Mortensen
Journal:  Arthritis Rheum       Date:  2000-02

5.  Increase in lifetime adverse drug reactions, service utilization, and disease severity among patients who will start COX-2 specific inhibitors: quantitative assessment of channeling bias and confounding by indication in 6689 patients with rheumatoid arthritis and osteoarthritis.

Authors:  Frederick Wolfe; Nancy Flowers; Thomas A Burke; Lester M Arguelles; Dan Pettitt
Journal:  J Rheumatol       Date:  2002-05       Impact factor: 4.666

6.  Hospitalization for gastrointestinal bleeding associated with non-steroidal anti-inflammatory drugs among elderly patients using low-dose aspirin: a retrospective cohort study.

Authors:  E Rahme; M Bardou; K Dasgupta; Y Toubouti; J Ghosn; A N Barkun
Journal:  Rheumatology (Oxford)       Date:  2006-07-13       Impact factor: 7.580

7.  Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial.

Authors:  Thomas J Schnitzer; Gerd R Burmester; Eduardo Mysler; Marc C Hochberg; Michael Doherty; Elena Ehrsam; Xavier Gitton; Gerhard Krammer; Bernhard Mellein; Patrice Matchaba; Alberto Gimona; Christopher J Hawkey
Journal:  Lancet       Date:  2004 Aug 21-27       Impact factor: 79.321

8.  Channelling bias and the incidence of gastrointestinal haemorrhage in users of meloxicam, coxibs, and older, non-specific non-steroidal anti-inflammatory drugs.

Authors:  T M MacDonald; S V Morant; J L Goldstein; T A Burke; D Pettitt
Journal:  Gut       Date:  2003-09       Impact factor: 23.059

9.  The upper gastrointestinal safety of rofecoxib vs. NSAIDs: an updated combined analysis.

Authors:  Douglas J Watson; Qinfen Yu; James A Bolognese; Alise S Reicin; Thomas J Simon
Journal:  Curr Med Res Opin       Date:  2004-10       Impact factor: 2.580

10.  Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison.

Authors:  P Emery; H Zeidler; T K Kvien; M Guslandi; R Naudin; H Stead; K M Verburg; P C Isakson; R C Hubbard; G S Geis
Journal:  Lancet       Date:  1999 Dec 18-25       Impact factor: 79.321
  10 in total
  1 in total

1.  Prevention of NSAID-related upper gastrointestinal toxicity: a meta-analysis of traditional NSAIDs with gastroprotection and COX-2 inhibitors.

Authors:  Alaa Rostom; Katherine Muir; Catherine Dube; Angel Lanas; Emilie Jolicoeur; Peter Tugwell
Journal:  Drug Healthc Patient Saf       Date:  2009-10-28
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.